Skip to main content

Non-Small Cell Lung Cancer

Hightower Clinical aimed to explore a drug’s potential role as a possible treatment option for advanced NSCLC and other solid tumors.

                       

About Non-Small Cell Lung Cancer Study

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of cases. It generally progresses more slowly than small cell lung cancer, often develops in the outer regions of the lungs, and includes various subtypes.

Hightower Clinical conducted a study to evaluate the safety and effectiveness of a bispecific antibody in patients with advanced NSCLC and other solid tumors. The goal was to test the drug as monotherapy or in combination with treatments like Osimertinib or chemotherapy.

Current Status

Not Recruiting

Study Count

1

Study Information

Non-Small Cell Lung Cancer

Study NameProtocol NumberSponsor
Non-Small Cell Lung Cancer

MCLA-129-CL01

Merus N.V.

Frequently Asked Questions

What is Non-Small Cell Lung Cancer (NSCLC)?

NSCLC is the most common type of lung cancer, accounting for about 85% of cases, and progresses more slowly than other forms of lung cancer.

What are the risk factors for NSCLC?

Risk factors for NSCLC include smoking, exposure to secondhand smoke, air pollution, and harmful substances like asbestos or radon, as well as a family history of lung cancer.

What complications can arise from NSCLC?

Complications of NSCLC can include difficulty breathing, chest pain, fatigue, and, if the cancer spreads, issues in other organs like the liver, bones, or brain.

Why should I participate in a study on NSCLC?

Participating in a study can help contribute to medical research, improve treatment options, and provide access to potential new therapies for managing advanced NSCLC.

Close Menu